Rydapt

Mastocytosis, Systemic, Hematologic Neoplasms, Acute Myeloid Leukemia

Treatment

8 FDA approvals

20 Active Studies for Rydapt

Treatment for

Mastocytosis, Systemic

What is Rydapt

MidostaurinThe Generic name of this drug

Treatment SummaryMidostaurin, also known as Rydapt, is a drug used to treat adult patients with newly diagnosed acute myeloid leukemia (AML) who have a genetic mutation called FLT3. It was approved by the FDA in 2017 and is used in combination with chemotherapy to increase the overall survival rate in AML patients.

Rydaptis the brand name

image of different drug pills on a surface

Rydapt Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Rydapt

Midostaurin

2017

Approved as Treatment by the FDA

Midostaurin, also known as Rydapt, is approved by the FDA for 8 uses such as Systemic Mastocytosis and Systemic Mastocytosis, Aggressive (ASM) .

Systemic Mastocytosis

Systemic Mastocytosis, Aggressive (ASM)

Mast Cell Leukemia (MCL)

Hematological Neoplasms

Acute Myeloid Leukemia (AML)

Used to treat Acute Myeloid Leukemia (AML) in combination with Cytarabine

Mastocytosis, Systemic

Acute Myeloid Leukemia

Used to treat Acute Myeloid Leukemia (AML) in combination with Cytarabine

Hematologic Neoplasms

Effectiveness

How Rydapt Affects PatientsMidostaurin works by targeting certain proteins (kinases) that can cause cancer, such as acute myeloid leukemia (AML) and advanced systemic mastocytosis (ASM). Taking midostaurin does not significantly affect heart rate. It can be used in combination with chemotherapy treatment to be more effective.

How Rydapt works in the bodyMidostaurin works by blocking multiple receptor proteins in the body. These proteins help control cell growth, and by stopping them, midostaurin can prevent the growth of cancer cells and leukemia cells. It also helps stop the growth of mast cells. Midostaurin also inhibits organic anion transporter and multidrug resistance protein, which can help it work more effectively.

When to interrupt dosage

The prescribed dosage of Rydapt is contingent upon the established condition, including Malignant mast cell neoplasm, Hematologic Neoplasms and Systemic Mastocytosis. The measure of dosage fluctuates with the administration approach (e.g. Capsule, liquid filled or Capsule, liquid filled - Oral) outlined in the table beneath.

Condition

Dosage

Administration

Mastocytosis, Systemic

25.0 mg,

, Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral

Hematologic Neoplasms

25.0 mg,

, Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral

Acute Myeloid Leukemia

25.0 mg,

, Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral

Warnings

There are 20 known major drug interactions with Rydapt.

Common Rydapt Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

The metabolism of (R)-warfarin can be decreased when combined with Midostaurin.

(S)-Warfarin

Major

The metabolism of (S)-Warfarin can be decreased when combined with Midostaurin.

1,2-Benzodiazepine

Major

The metabolism of 1,2-Benzodiazepine can be decreased when combined with Midostaurin.

3,5-diiodothyropropionic acid

Major

The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Midostaurin.

5-androstenedione

Major

The metabolism of 5-androstenedione can be decreased when combined with Midostaurin.

Rydapt Toxicity & Overdose RiskMidostaurin has been linked to decreased fertility in both male and female rats. The lowest toxic dose in mice, rats, and rabbits is 300mg/kg, 980mg/kg, and 3200mg/kg respectively. Some patients have also experienced pulmonary toxicity, including lung disease and inflammation of the lungs, when taking midostaurin alone or in combination with other drugs.

Rydapt Novel Uses: Which Conditions Have a Clinical Trial Featuring Rydapt?

312 active clinical trials are presently assessing the potential of Rydapt in providing therapeutic benefit for Acute Myeloid Leukemia, Hematologic Neoplasms and Systemic Mastocytosis.

Condition

Clinical Trials

Trial Phases

Hematologic Neoplasms

0 Actively Recruiting

Mastocytosis, Systemic

0 Actively Recruiting

Acute Myeloid Leukemia

274 Actively Recruiting

Phase 2, Phase 1, Phase 3, Phase 4, Not Applicable, Early Phase 1

Patient Q&A Section about rydapt

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is RYDAPT used for?

"An oral prescription medicine called RYDAPT is used to treat aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL) in adults."

Answered by AI

Is midostaurin a chemo drug?

"Midostaurin is a type of targeted cancer drug. Daunorubicin and cytarabine are chemotherapy drugs. Midostaurin is pronounced MY-doh-STAW-rin. You pronounce daunorubicin as DAW-noh-ROO-bih-sin and cytarabine as sye-TARE-a-been. This combination of cancer drugs is a treatment for acute myeloid leukaemia (AML)."

Answered by AI

Is RYDAPT chemotherapy?

"Rydapt is not a chemotherapy drug, but it is used to treat certain types of cancer, including acute myeloid leukemia. Chemotherapy drugs kill cells that grow and divide quickly."

Answered by AI

How effective is RYDAPT?

"In a clinical study, Rydapt was effective in treating certain types of systemic mastocytosis. In this study, 21% of people taking Rydapt alone had complete remission or partial remission. These results were reported after six cycles of treatment."

Answered by AI